Amiodarone to Prevent Recurrence of Atrial Fibrillation
Denis Roy, M.D., Mario Talajic, M.D., Paul Dorian, M.D., Stuart Connolly, M.D., Mark J. Eisenberg, M.D., M.P.H., Martin Green, M.D., Teresa Kus, M.D., Jean Lambert, Ph.D., Marc Dubuc, M.D., Pierre Gagné, M.D., Stanley Nattel, M.D., Bernard Thibault, M.D., for The Canadian Trial of Atrial Fibrillation Investigators
Background The restoration and maintenance of sinus rhythm isa desirable goal in patients with atrial fibrillation, becausethe prevention of recurrences can improve cardiac function andrelieve symptoms. Uncontrolled studies have suggested that amiodaronein low doses may be more effective and safer than other agentsin preventing recurrence, but this agent has not been testedin a large, randomized trial.
Methods We undertook a prospective, multicenter trial to testthe hypothesis that low doses of amiodarone would be more efficaciousin preventing recurrent atrial fibrillation than therapy withsotalol or propafenone. We randomly assigned patients who hadhad at least one episode of atrial fibrillation within the previoussix months to amiodarone or to sotalol or propafenone, givenin an open-label fashion. The patients in the group assignedto sotalol or propafenone underwent a second randomization todetermine whether they would receive sotalol or propafenonefirst; if the first drug was unsuccessful the second agent wasprescribed. Loading doses of the drugs were administered andelectrical cardioversion was performed (if necessary) within21 days after randomization for all patients in both groups.The follow-up period began 21 days after randomization. Theprimary end point was the length of time to a first recurrenceof atrial fibrillation.
Results Of the 403 patients in the study, 201 were assignedto amiodarone and 202 to either sotalol (101 patients) or propafenone(101 patients). After a mean of 16 months of follow-up, 71 ofthe patients who were assigned to amiodarone (35 percent) and127 of those who were assigned to sotalol or propafenone (63percent) had a recurrence of atrial fibrillation (P<0.001).Adverse events requiring the discontinuation of drug therapyoccurred in 18 percent of the patients receiving amiodarone,as compared with 11 percent of those treated with sotalol orpropafenone (P=0.06).
Conclusions Amiodarone is more effective than sotalol or propafenonefor the prevention of recurrences of atrial fibrillation.
Source Information
From the Montreal Heart Institute, Montreal (D.R., M.T., M.J.E., J.L., M.D., P.G., S.N., B.T.); St. Michael's Hospital, Toronto (P.D.); Hamilton General Hospital and McMaster University, Hamilton, Ont. (S.C.); the University of Ottawa Heart Institute, Ottawa, Ont. (M.G.); and Hôpital du Sacré-Cur de Montréal, Montreal (T.K.) all in Canada.
Address reprint requests to Dr. Roy at the Montreal Heart Institute, 5000 Belanger St. E., Montreal, QC H1T 1C8, Canada, or at roy{at}icm.umontreal.ca.
Camm, A. J., Reiffel, J. A.
(2008). Defining endpoints in clinical trials on atrial fibrillation. Eur Heart J Suppl
10: H55-H78
[Abstract][Full Text]
Aliot, E., Ruskin, J. N.
(2008). Controversies in ablation of atrial fibrillation. Eur Heart J Suppl
10: H32-H54
[Abstract][Full Text]
Noheria, A., Kumar, A., Wylie, J. V. Jr, Josephson, M. E.
(2008). Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation: A Systematic Review. Arch Intern Med
168: 581-586
[Abstract][Full Text]
Ehrlich, J. R., Biliczki, P., Hohnloser, S. H., Nattel, S.
(2008). Atrial-Selective Approaches for the Treatment of Atrial Fibrillation. J Am Coll Cardiol
51: 787-792
[Abstract][Full Text]
Cosio, F. G., Aliot, E., Botto, G. L., Heidbuchel, H., Geller, C. J., Kirchhof, P., De Haro, J.-C., Frank, R., Villacastin, J. P., Vijgen, J., Crijns, H.
(2008). Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace
10: 21-27
[Abstract][Full Text]
Marine, J. E.
(2007). Catheter Ablation Therapy for Supraventricular Arrhythmias. JAMA
298: 2768-2778
[Abstract][Full Text]
Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G.
(2007). Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J
28: 2803-2817
[Abstract][Full Text]
Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G.
(2007). Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace
9: 1006-1023
[Abstract][Full Text]
Vassallo, P., Trohman, R. G.
(2007). Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications. JAMA
298: 1312-1322
[Abstract][Full Text]
Singh, B. N., Connolly, S. J., Crijns, H. J.G.M., Roy, D., Kowey, P. R., Capucci, A., Radzik, D., Aliot, E. M., Hohnloser, S. H., the EURIDIS and ADONIS Investigators,
(2007). Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. NEJM
357: 987-999
[Abstract][Full Text]
Ezekowitz, M. D.
(2007). Maintaining Sinus Rhythm -- Making Treatment Better Than the Disease. NEJM
357: 1039-1041
[Full Text]
Singh, B. N., Aliot, E.
(2007). Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity?. Eur Heart J Suppl
9: G17-G25
[Abstract][Full Text]
Shantsila, E., Watson, T., Lip, G. Y.
(2007). Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace
9: iv37-iv44
[Abstract][Full Text]
Essebag, V., Reynolds, M. R., Hadjis, T., Lemery, R., Olshansky, B., Buxton, A. E., Josephson, M. E., Zimetbaum, P.
(2007). Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation. Arch Intern Med
167: 1648-1653
[Abstract][Full Text]
Conen, D., Melly, L., Kaufmann, C., Bilz, S., Ammann, P., Schaer, B., Sticherling, C., Muller, B., Osswald, S.
(2007). Amiodarone-Induced Thyrotoxicosis: Clinical Course and Predictors of Outcome. J Am Coll Cardiol
49: 2350-2355
[Abstract][Full Text]
Freudenberger, R. S., Hellkamp, A. S., Halperin, J. L., Poole, J., Anderson, J., Johnson, G., Mark, D. B., Lee, K. L., Bardy, G. H., for the SCD-HeFT Investigators,
(2007). Risk of Thromboembolism in Heart Failure: An Analysis From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation
115: 2637-2641
[Abstract][Full Text]
Nattel, S., Maguy, A., Le Bouter, S., Yeh, Y.-H.
(2007). Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation. Physiol. Rev.
87: 425-456
[Abstract][Full Text]
Mykytsey, A., Bauman, J. L., Razminia, M., Zheutlin, T., Wang, T., Saleem, M., Leal, S., Kehoe, R. F.
(2007). Observations on the Safety and Effectiveness of Dofetilide in Patients With Paroxysmal Atrial Fibrillation and Normal Left Ventricular Function. J CARDIOVASC PHARMACOL THER
12: 36-43
[Abstract]
Zimetbaum, P.
(2007). Amiodarone for Atrial Fibrillation. NEJM
356: 935-941
[Full Text]
Sulke, N, Sayers, F, Lip, G Y H, on behalf of the Guideline Development Group for t,
(2007). Rhythm control and cardioversion. Heart
93: 29-34
[Full Text]
Pappone, C., Augello, G., Sala, S., Gugliotta, F., Vicedomini, G., Gulletta, S., Paglino, G., Mazzone, P., Sora, N., Greiss, I., Santagostino, A., LiVolsi, L., Pappone, N., Radinovic, A., Manguso, F., Santinelli, V.
(2006). A Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial Fibrillation: The APAF Study. J Am Coll Cardiol
48: 2340-2347
[Abstract][Full Text]
Da Costa, A., Thevenin, J., Roche, F., Romeyer-Bouchard, C., Abdellaoui, L., Messier, M., Denis, L., Faure, E., Gonthier, R., Kruszynski, G., Pages, J. M., Bonijoly, S., Lamaison, D., Defaye, P., Barthelemy, J. C., Gouttard, T., Isaaz, K., for the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LAD,
(2006). Results From the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) Trial on Atrial Flutter, a Multicentric Prospective Randomized Study Comparing Amiodarone and Radiofrequency Ablation After the First Episode of Symptomatic Atrial Flutter. Circulation
114: 1676-1681
[Abstract][Full Text]
Lombardi, F., Borggrefe, M., Ruzyllo, W., Luderitz, B., for the A-COMET-II Investigators,
(2006). Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur Heart J
27: 2224-2231
[Abstract][Full Text]
Wadhani, N., Sarma, J. S., Singh, B. N., Radzik, D., Gaud, C.
(2006). Dose-Dependent Effects of Oral Dronedarone on the Circadian Variation of RR and QT Intervals in Healthy Subjects: Implications for Antiarrhythmic Actions.. J CARDIOVASC PHARMACOL THER
11: 184-190
[Abstract]
Writing Committee Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L.
(2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace
8: 651-745
[Full Text]
Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S.
(2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol
48: e149-e246
[Full Text]
Falk, R. H.
(2006). Atrial Fibrillation or Sinus Rhythm?: Controversy and Contradiction in Quality of Life Outcomes. J Am Coll Cardiol
48: 731-733
[Full Text]
Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L.
(2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation
114: e257-e354
[Full Text]
Schrickel, J. W., Schwab, J. O., Yang, A., Bielik, H., Bitzen, A., Luderitz, B., Lewalter, T.
(2006). Pro-arrhythmic effects of amiodarone and concomitant rate-control medication. Europace
8: 403-407
[Abstract][Full Text]
O'Sullivan, A. J, Lewis, M., Diamond, T.
(2006). Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality.. Eur J Endocrinol
154: 533-536
[Abstract][Full Text]
Gulizia, M., Mangiameli, S., Chiaranda, G., Spadola, V., Di Giovanni, N., Colletti, A., Bulla, V., Circo, A., Pensabene, O., Vasquez, L., Vaccaro, I., Grammatico, A., on behalf of PITAGORA Study Investigators,
(2006). Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.. Europace
8: 302-305
[Abstract][Full Text]
Stabile, G., Bertaglia, E., Senatore, G., De Simone, A., Zoppo, F., Donnici, G., Turco, P., Pascotto, P., Fazzari, M., Vitale, D. F.
(2006). Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J
27: 216-221
[Abstract][Full Text]
Singh, B. N.
(2005). {beta}-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview. J CARDIOVASC PHARMACOL THER
10: S3-S14
[Abstract]
Verma, A., Natale, A., Padanilam, B. J., Prystowsky, E. N., Verma, A., Natale, A., Padanilam, B. J., Prystowsky, E. N.
(2005). Why Atrial Fibrillation Ablation Should Be Considered First-Line Therapy for Some Patients. Circulation
112: 1214-1222
[Full Text]
Padanilam, B. J., Prystowsky, E. N.
(2005). Should Ablation Be First-Line Therapy and for Whom: The Antagonist Position. Circulation
112: 1223-1231
[Full Text]
Rubinstein, J., Zimetbaum, P. J., Josephson, M. E., Schlegel, A., Desai, K. R., Singh, B. N., Singh, S. N., Reda, D.
(2005). Amiodarone versus sotalol for atrial fibrillation.. NEJM
353: 627-630
[Full Text]
Martinez, E. A., Bass, E. B., Zimetbaum, P.
(2005). Pharmacologic Control of Rhythm: American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery. Chest
128: 48S-55S
[Abstract][Full Text]
Martinez, E. A., Epstein, A. E., Bass, E. B.
(2005). Pharmacologic Control of Ventricular Rate: American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery. Chest
128: 56S-60S
[Abstract][Full Text]
Hoit, B. D.
(2005). Assessing Atrial Mechanical Remodeling and Its Consequences. Circulation
112: 304-306
[Full Text]
Wadhani, N., Singh, B. N.
(2005). Prolongation of Repolarization as Antifibrillatory Action Revisited: Drug Combination Therapy in Atrial Fibrillation. J CARDIOVASC PHARMACOL THER
10: 149-152
Falk, R. H.
(2005). Rate Control Is Preferable to Rhythm Control in the Majority of Patients With Atrial Fibrillation. Circulation
111: 3141-3150
[Full Text]
Zimetbaum, P.
(2005). An Argument for Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Circulation
111: 3150-3156
[Full Text]
Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., Lewis, H. D. Jr., Raisch, D. W., Ezekowitz, M. D., the Sotalol Amiodarone Atrial Fibrillation Efficac,
(2005). Amiodarone versus Sotalol for Atrial Fibrillation. NEJM
352: 1861-1872
[Abstract][Full Text]
Geidel, S., Ostermeyer, J., Lass, M., Betzold, M., Duong, A., Jensen, F., Boczor, S., Kuck, K.-H.
(2005). Three years experience with monopolar and bipolar radiofrequency ablation surgery in patients with permanent atrial fibrillation. Eur. J. Cardiothorac. Surg.
27: 243-249
[Abstract][Full Text]
Zohar, P., Kovacic, M., Brezocnik, M., Podbregar, M.
(2005). Prediction of maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation by non-deterministic modelling. Europace
7: 500-507
[Abstract][Full Text]
Sticherling, C., Behrens, S., Kamke, W., Stahn, A., Zabel, M.
(2005). Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. Europace
7: 546-553
[Abstract][Full Text]
Hsu, L.-F., Jais, P., Sanders, P., Garrigue, S., Hocini, M., Sacher, F., Takahashi, Y., Rotter, M., Pasquie, J.-L., Scavee, C., Bordachar, P., Clementy, J., Haissaguerre, M.
(2004). Catheter Ablation for Atrial Fibrillation in Congestive Heart Failure. NEJM
351: 2373-2383
[Abstract][Full Text]
Page, R. L.
(2004). Newly Diagnosed Atrial Fibrillation. NEJM
351: 2408-2416
[Full Text]
Fetsch, T., Breithardt, G.
(2004). Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J
25: 2174-2175
[Full Text]
Zimetbaum, P., Josephson, M. E.
(2004). Is There a Role for Maintaining Sinus Rhythm in Patients with Atrial Fibrillation?. ANN INTERN MED
141: 720-726
[Abstract][Full Text]
Dorian, P., Mangat, I., Pinter, A., Korley, V.
(2004). The Burden of Atrial Fibrillation: Should We Abandon Antiarrhythmic Drug Therapy?. J CARDIOVASC PHARMACOL THER
9: 257-262
[Abstract]
Humphries, K. H., Kerr, C. R., Steinbuch, M., Dorian, P., for The Canadian Registry of Atrial Fibrillation,
(2004). Limitations to antiarrhythmic drug use in patients with atrial fibrillation. CMAJ
171: 741-745
[Abstract][Full Text]
Boos, C, Ritzema, J, More, R S
(2004). A short course of oral amiodarone improves sinus rhythm maintenance post-cardioversion for atrial fibrillation. Heart
90: 1063-1064
[Full Text]
Endorsed by the Mediterranean Society of Pacing an, , WRITING COMMITTEE MEMBERS, , McNamara, R. L., Brass, L. M., Drozda, J. P. Jr, Go, A. S., Halperin, J. L., Kerr, C. R., Levy, S., Malenka, D. J., Mittal, S., Pelosi, F. Jr, Rosenberg, Y., Stryer, D., Wyse, D. G., TASK FORCE MEMBERS, , Radford, M. J., Goff, D. C. Jr, Grover, F. L., Heidenreich, P. A., Malenka, D. J., Peterson, E. D., Redberg, R. F.
(2004). ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation
109: 3223-3243
[Full Text]
John, R. M., Michaud, G.
(2004). Atrial Fibrillation: Nonpharmacologic Therapies Coming of Age. Chest
125: 1977-1979
[Full Text]
Vora, A., Karnad, D., Goyal, V., Naik, A., Gupta, A., Lokhandwala, Y., Kulkarni, H., Singh, B. N.
(2004). Control of Heart Rate Versus Rhythm in Rheumatic Atrial Fibrillation: A Randomized Study. J CARDIOVASC PHARMACOL THER
9: 65-73
[Abstract]
Kochiadakis, G. E., Igoumenidis, N. E., Hamilos, M. I., Tzerakis, P. G., Klapsinos, N. C., Zacharis, E. A., Vardas, P. E.
(2004). Long-term Maintenance of Normal Sinus Rhythm in Patients With Current Symptomatic Atrial Fibrillation: Amiodarone vs Propafenone, Both in Low Doses. Chest
125: 377-383
[Abstract][Full Text]
Fang, M. C., Stafford, R. S., Ruskin, J. N., Singer, D. E.
(2004). National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial Fibrillation. Arch Intern Med
164: 55-60
[Abstract][Full Text]
Channer, K. S., Birchall, A., Steeds, R. P., Walters, S. J., Yeo, W. W., West, J. N., Muthusamy, R., Rhoden, W. E., Saeed, B. T., Batin, P., Brooksby, W.P., Wilson, I., Grant, S.
(2004). A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J
25: 144-150
[Abstract][Full Text]
Snow, V., Weiss, K. B., LeFevre, M., McNamara, R., Bass, E., Green, L. A., Michl, K., Owens, D. K., Susman, J., Allen, D. I., Mottur-Pilson, C., the Joint AAFP/ACP Panel on Atrial Fibrillation,
(2003). Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians. ANN INTERN MED
139: 1009-1017
[Abstract][Full Text]
McNamara, R. L., Tamariz, L. J., Segal, J. B., Bass, E. B.
(2003). Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. ANN INTERN MED
139: 1018-1033
[Abstract][Full Text]
Geller, J.C., Reek, S., Timmermans, C., Kayser, T., Tse, H.-F., Wolpert, C., Jung, W., Camm, A.J., Lau, C.-P., Wellens, H. J.J., Klein, H. U.
(2003). Treatment of atrial fibrillation with an implantable atrial defibrillator -- long term results. Eur Heart J
24: 2083-2089
[Abstract][Full Text]
Kasliwal, R. R, Mukesh, S., Manohar, G., Aggarwal, N., Bhatia, A.
(2003). Pharmacotherapy of Atrial Fibrillation. Asian Cardiovasc. Thorac. Ann.
11: 364-374
[Abstract][Full Text]
Boos, C.J., Carlsson, J., More, R.S.
(2003). Rate or rhythm control in persistent atrial fibrillation?. QJM
96: 881-892
[Abstract][Full Text]
Singh, B. N.
(2003). More on Amiodarone-Meeting the Challenges of the Combined Epidemics of Heart Failure and Atrial Fibrillation?. J CARDIOVASC PHARMACOL THER
8: 175-178
Galperin, J., Elizari, M. V., Chiale, P. A., Molina, R. T., Ledesma, R., Scapin, A. O., Blanco, M. V., Bonato, R., Lago, M., Grupo de Estudio de Fibrilacion Auricular Con Amio,
(2003). Pharmacologic Reversion of Persistent Atrial Fibrillation with Amiodarone Predicts Long-Term Sinus Rhythm Maintenance. J CARDIOVASC PHARMACOL THER
8: 179-186
[Abstract]
Capucci, A., Aschieri, D.
(2003). Antiarrhythmic drug therapy: what is certain and what is to come. Eur Heart J Suppl
5: H8-H18
[Abstract]
Carlson, M. D., Ip, J., Messenger, J., Beau, S., Kalbfleisch, S., Gervais, P., Cameron, D. A., Duran, A., Val-Mejias, J., Mackall, J., Gold, M., ADOPT Investigators,
(2003). A new pacemaker algorithm for the treatment of atrial fibrillation: Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol
42: 627-633
[Abstract][Full Text]
Touboul, P., Brugada, J., Capucci, A., Crijns, H. J.G.M., Edvardsson, N., Hohnloser, S. H.
(2003). Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J
24: 1481-1487
[Abstract][Full Text]
Markides, V., Schilling, R. J
(2003). Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart
89: 939-943
[Full Text]
Pappone, C., Rosanio, S., Augello, G., Gallus, G., Vicedomini, G., Mazzone, P., Gulletta, S., Gugliotta, F., Pappone, A., Santinelli, V., Tortoriello, V., Sala, S., Zangrillo, A., Crescenzi, G., Benussi, S., Alfieri, O.
(2003). Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: Outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol
42: 185-197
[Abstract][Full Text]
The AFFIRM First Antiarrhythmic Drug Substudy Inve,
(2003). Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol
42: 20-29
[Abstract][Full Text]
Dorian, P., Mangat, I.
(2003). Restoring sinus rhythm in atrial fibrillation: A pyrrhic victory?. J Am Coll Cardiol
42: 30-32
[Full Text]
Geidel, S., Lass, M., Boczor, S., Kuck, K.-H., Ostermeyer, J.
(2003). Surgical treatment of permanent atrial fibrillation during heart valve surgery. ICVTS
2: 160-165
[Abstract][Full Text]
Malhotra, A., Muse, V. V., Mark, E. J.
(2003). Case 12-2003 - An 82-Year-Old Man with Dyspnea and Pulmonary Abnormalities. NEJM
348: 1574-1585
[Full Text]
Letelier, L. M., Udol, K., Ena, J., Weaver, B., Guyatt, G. H.
(2003). Effectiveness of Amiodarone for Conversion of Atrial Fibrillation to Sinus Rhythm: A Meta-analysis. Arch Intern Med
163: 777-785
[Abstract][Full Text]
Shinagawa, K., Shiroshita-Takeshita, A., Schram, G., Nattel, S.
(2003). Effects of Antiarrhythmic Drugs on Fibrillation in the Remodeled Atrium: Insights Into the Mechanism of the Superior Efficacy of Amiodarone. Circulation
107: 1440-1446
[Abstract][Full Text]
Ott, M. C., Khoor, A., Leventhal, J. P., Paterick, T. E., Burger, C. D.
(2003). Pulmonary Toxicity in Patients Receiving Low-Dose Amiodarone. Chest
123: 646-651
[Abstract][Full Text]
Essebag, V., Hadjis, T., Platt, R. W., Pilote, L.
(2003). Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol
41: 249-254
[Abstract][Full Text]
Lozano, I. F., Vincent, A., Roda, J., Méndez, M., Ferrer, J. M. M., Andrade, F., Manzano, J. J., Ceres, R., Errejon, J., Toquero, J.
(2003). Paroxysmal atrial fibrillation prevention by pacing in patients with pacemaker indication. Europace
5: 267-273
[Abstract][Full Text]
Savelieva, I., John Camm, A.
(2003). Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace
5: S5-S19
[Abstract][Full Text]
Pitt, A. D, Fernandes, C., Bewick, N. L, Hemsworth, P. D, Buhagiar, K. A, Hansen, P. S, Rasmussen, H. H, Delbridge, L., Whalley, D. W
(2003). Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone. Cardiovasc Res
57: 101-108
[Abstract][Full Text]
Falk, R. H.
(2002). Management of Atrial Fibrillation -- Radical Reform or Modest Modification?. NEJM
347: 1883-1884
[Full Text]
Khairy, P., Nattel, S.
(2002). New insights into the mechanisms and management of atrial fibrillation. CMAJ
167: 1012-1020
[Abstract][Full Text]
Fynn, S. P., Garratt, C. J.
(2002). The effectiveness of serial cardioversion therapy for recurrence of atrial fibrillation. Eur Heart J
23: 1487-1489
[Full Text]
Wong, C-K, White, H D, Wilcox, R G, Criger, D A, Califf, R M, Topol, E J, Ohman, E M
(2002). Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Heart
88: 357-362
[Abstract][Full Text]
Blaauw, Y, Van Gelder, I C, Crijns, H J G M
(2002). Treatment of atrial fibrillation. Heart
88: 432-437
[Full Text]
Sami, M.
(2002). Are we ready for dual-site right atrial pacing?. J Am Coll Cardiol
40: 1151-1152
[Full Text]
Singh, B. N.
(2002). Atrial Fibrillation Following Investigation of Rhythm Management: AFFIRM Trial Outcomes. What Might Be Their Implications for Arrhythmia Control?. J CARDIOVASC PHARMACOL THER
7: 131-133
Madrid, A. H., Bueno, M. G., Rebollo, J. M.G., Marin, I., Pena, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., Moro, C.
(2002). Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study. Circulation
106: 331-336
[Abstract][Full Text]